Glaxo to pay $750m over adulterated drug claims

The drug company GlaxoSmithKline PLC will pay $750m (€542m) to settle allegations that it knowingly manufactured and sold adulterated drugs, federal prosecutors in the US said yesterday.

US Attorney Carmen Ortiz said the London-based company will pay $150m in criminal fines and $600m in civil penalties related to faulty manufacturing processes at its plant in Cidra, Puerto Rico.